CoreCap Advisors LLC Purchases 24,717 Shares of Boston Scientific Co. (NYSE:BSX)

CoreCap Advisors LLC increased its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 541.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 29,282 shares of the medical equipment provider's stock after purchasing an additional 24,717 shares during the quarter. CoreCap Advisors LLC's holdings in Boston Scientific were worth $2,615,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Crestline Management LP purchased a new position in shares of Boston Scientific during the 4th quarter valued at $2,974,000. Castle Hook Partners LP grew its holdings in shares of Boston Scientific by 146.9% in the fourth quarter. Castle Hook Partners LP now owns 762,073 shares of the medical equipment provider's stock valued at $68,068,000 after purchasing an additional 453,374 shares in the last quarter. Cetera Investment Advisers grew its stake in shares of Boston Scientific by 4.9% in the 4th quarter. Cetera Investment Advisers now owns 319,161 shares of the medical equipment provider's stock worth $28,507,000 after buying an additional 14,789 shares in the last quarter. Blue Capital Inc. bought a new stake in Boston Scientific during the fourth quarter worth approximately $841,000. Finally, Brevan Howard Capital Management LP increased its position in shares of Boston Scientific by 196.3% during the 4th quarter. Brevan Howard Capital Management LP now owns 97,340 shares of the medical equipment provider's stock valued at $8,694,000 after purchasing an additional 64,489 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

NYSE BSX opened at $104.81 on Thursday. The stock has a market capitalization of $155.06 billion, a price-to-earnings ratio of 83.85, a PEG ratio of 2.79 and a beta of 0.68. The stock has a 50-day moving average of $98.73 and a 200 day moving average of $95.72. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the prior year, the company posted $0.56 EPS. The business's quarterly revenue was up 20.9% on a year-over-year basis. Sell-side analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BSX shares. Robert W. Baird upped their price target on shares of Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Needham & Company LLC raised their price target on Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Stifel Nicolaus upped their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research note on Friday, January 10th. Finally, UBS Group increased their target price on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Twenty-three equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $114.52.

Insider Buying and Selling

In other news, EVP John Bradley Sorenson sold 6,528 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the transaction, the executive vice president now directly owns 26,449 shares in the company, valued at $2,776,351.53. The trade was a 19.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the sale, the chief executive officer now directly owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. This represents a 9.67 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 307,025 shares of company stock worth $31,742,060. Insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.